ArticlePloS one2022
The impact of the government response on pandemic control in the long run-A dynamic empirical analysis based on COVID-19.
Article in PloS one, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Socioeconomic disparities in risk perceptions and precautionary actions against COVID-19 among the working age population aged 18-59 in Japan: a cross-sectional study.BMJ public health · 2024Article
- Serological survey in a university community after the fourth wave of COVID-19 in Senegal.PloS one · 2024Article
- The role of civil society organizations (CSOs) in the COVID-19 response across the Global South: A multinational, qualitative study.PLOS global public health · 2023Article
- The COVID-19 pandemic reveals the wide-ranging role of biobanks.Frontiers in public health · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeAlthough the outbreak of the Corona Virus Disease 2019 (COVID-19) occurred on a global scale, governments from different countries adopted different policies and achieved different anti-epidemic effects. The purpose of this study is to investigate whether and how the government response affected the transmission scale of COVID-19 on the dynamic perspective. METHODOLOGY: This paper uses a dynamic generalized moment method to research the relationship between the government response and COVID-19 case fatality rate by using panel data from eight countries: China, United States, Canada, Australia, Italy, France, Japan, and South Korea.
findingsWe have the following findings: 1. Government responses have a significant impact on the scale of COVID-19 transmission. 2. The rate of increase of government responses on the growth rate of COVID-19 case fatality rate has the characteristics of cyclicity and repeatability, that is, with the increase in the growth rate of government responses, the COVID-19 case fatality rate shows the following cyclical motion law: increasing first, reaching the maximum point, and then declining, and finally reaching the minimum point and then rising; ultimately, its convergence becomes 0. The cyclical fluctuations of COVID-19 in the long term may be caused by the decline in the level of government response, the mutation of the virus, and the violation of restrictive policies by some citizens. 3. The government response has a lag in controlling the spread of COVID-19. ORIGINALITY/VALUE: Since there is a lack of literature on the impact of government responses on the development of COVID-19 from a long-term and dynamic perspective. This paper fills this gap in empirical research. We provide and expand new empirical evidence based on the current literature. This paper provides the basis for government decision-making and will help to formulate the response to other major public health events that may occur in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.